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Background: Effective methods for eradicating cancer stem cells (CSCs), which are highly tumorigenic and resistant to
conventional therapies, are urgently needed. Our previous studies demonstrated that survivin-responsive conditionally
replicating adenoviruses regulated with multiple factors (Surv.m-CRAs), which selectively replicate in and kill a broad
range of cancer-cell types, are promising anticancer agents. Here we examined the therapeutic potentials of a
Surv.m-CRA against rhabdomyosarcoma stem cells (RSCs), in order to assess its clinical effectiveness and usefulness.
Methods: Our previous study demonstrated that fibroblast growth factor receptor 3 (FGFR3) is a marker of RSCs. We
examined survivin mRNA levels, survivin promoter activities, relative cytotoxicities of Surv.m-CRA in RSC-enriched
(serum-minus) vs. RSC-exiguous (serum-plus) and FGFR3-positive vs. FGFR3-negative sorted rhabdomyosarcoma cells,
and the in vivo therapeutic effects of Surv.m-CRAs on subcutaneous tumors in mice.
Results: Both survivin mRNA levels and survivin promoter activities were significantly elevated under RSC-enriched relative
to RSC-exiguous culture conditions, and the elevation was more prominent in FGFR3-positive vs. FGFR3-negative sorted
cells than in RSC-enriched vs. RSC-exiguous conditions. Although Surv.m-CRA efficiently replicated and potently induced
cell death in all populations of rhabdomyosarcoma cells, the cytotoxic effects were more pronounced in RSC-enriched or
RSC-purified cells than in RSC-exiguous or progeny-purified cells. Injections of Surv.m-CRAs into tumor nodules generated
by transplanting RSC-enriched cells induced significant death of rhabdomyosarcoma cells and regression of tumor nodules.
Conclusions: The unique therapeutic features of Surv.m-CRA, i.e., not only its therapeutic effectiveness against all cell
populations but also its increased effectiveness against CSCs, suggest that Surv.m-CRA is promising anticancer agent.
Keywords: Cancer stem cells, Conditionally replicating adenovirus, Fibroblast growth factor receptor 3, Gene therapy,
Oncolytic adenovirus, Promoter, Rhabdomyosarcoma, Survivin, Tumor-initiating cell, VirotherapyBackground
Accumulating data have suggested that cancer stem cells
(CSCs), also called tumor-initiating cells, are a small but
specialized population of tumor cells that possess high
capacity for tumor initiation, invasion, and metastasis, as
well as for self-renewal [1]. After most cells in the tumor
are killed by conventional chemotherapy or radio-
therapy, residual CSCs are believed to give rise to the
bulk populations of tumor-cell progeny and recapitulate
the original tumor nodule [2]. From the standpoints* Correspondence: kosai@m2.kufm.kagoshima-u.ac.jp
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stated.of clinical oncology and therapeutics, the most critical
feature of CSCs is that they are highly resistant to con-
ventional chemoradiotherapies [3,4], because they are
predominantly in a dormant or slow-growing phase of
the cell cycle [3] and they express high levels of multiple
drug-resistance transporters [4]. Because the poor prog-
nosis of patients with malignant tumors is caused, at
least in part, by CSCs, the development of effective ther-
apies against CSCs is urgently needed.
Rhabdomyosarcoma is the most common soft-tissue ma-
lignancy in children and adolescents [5]. Metastatic rha-
bdomyosarcoma is often incurable, and is associated with
poor prognosis; approximately 20% of rhabdomyosarcomaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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[6]. Whereas current treatment for rhabdomyosarcoma
relies on chemotherapy, the cytotoxic actions of chemo-
therapeutic agents are not only ineffective but also non–
tumor-specific in treatment of advanced and metastatic
tumors. Therefore, these agents can impair normal devel-
opment and cause secondary cancers in some growing chil-
dren [5]. To develop a novel and innovative therapy against
malignant rhabdomyosarcoma, we previously identified
rhabdomyosarcoma stem cells (RSCs) and showed that
fibroblast growth factor receptor 3 (FGFR3) is a marker of
RSCs [7]. For instance, implantation of a single FGFR3-
positive KYM-1 rhabdomyosarcoma cell can form a tumor
nodule in vivo consisting of histologically defined rhabdo-
myosarcoma cells, whereas a single FGFR3-negative cell
cannot form such nodules [7]. Likewise, the careful analyses
in our previous study characterized FGFR3-positive rhabdo-
myosarcoma cells as RSCs.
Conditionally replicating adenoviruses (CRAs), also
called oncolytic adenoviruses, replicate predominantly in
tumor cells, which they kill via apoptosis mediated by
adenoviral proteins; therefore, CRAs are promising anti-
cancer agents [8,9]. We previously developed a method
to efficiently construct diverse CRAs that can specifically
target and/or efficiently treat malignant tumors using
multiple factors (m-CRAs) [10]. Our m-CRA construc-
tion system expedited the process of generating, mo-
difying, and testing diverse m-CRAs with the goal of
developing an ideal m-CRA for tumor therapy; indeed,
our m-CRA strategy increased the potential cancer spe-
cificity of virotherapy [10-12]. Survivin, a new member
of the inhibitor of apoptosis (IAP) gene family, is expres-
sed at high levels in cancerous but not normal tissues,
and high survivin expression levels are positively corre-
lated with poor prognosis, an accelerated rate of recur-
rence, and increased resistance to therapy in cancer
patients [13,14]. We developed several types of survivin-
responsive m-CRAs (Surv.m-CRAs) in which adenoviral
E1A was regulated by the promoter of survivin; in some
versions of these viruses, the p53-binding domain in
E1B was deleted (i.e., E1B55KD), the Rb-binding domain
in E1A was deleted, or the native E1B promoter was re-
placed with another cancer-specific promoter [11,12]. All
Surv.m-CRAs induced potent in vitro and in vivo cyto-
toxic effects against a variety of malignant tumors, and ex-
hibited stronger and more cancer-selective phenotypes
than telomerase reverse transcriptase (Tert)-responsive
m-CRAs (Tert.m-CRAs), which are currently among the
best CRAs [11,12]. Furthermore, certain types of Surv.m-
CRAs significantly increased cancer specificity (i.e., safety)
without reduced anticancer effects [11].
CSCs are resistant to conventional chemoradiothera-
pies, and the therapeutic potentials of Surv.m-CRAs
against CSCs have not been well examined. In order toevaluate the clinical usefulness of Surv.m-CRAs against
malignant and incurable tumors, it will be necessary to
perform careful comparative studies of endogenous sur-
vivin expression levels, activity of transduced survivin
promoters, and relative antitumor effects on CSCs and
their progeny. More generally and importantly, it has
not yet been clearly elucidated whether transcriptional
targeting using CRAs is a useful strategy for treating
CSCs. Because FGFR3-positive RSCs are a useful model
for CSCs, we examined the biological features of survi-
vin and compared the therapeutic potentials of Surv.m-
CRA against RSCs and progeny tumor cells.
Methods
Cells and cell culture
KYM-1 cell lines were purchased from Health Sciences
Research Resources Bank (Tokyo, Japan). KYM-1 cells
were cultured in DMEM, supplemented with 10% FCS,
100 units/ml penicillin G, and 100 μg/ml streptomycin
(Invitrogen, Carlsbad, CA, USA). In some experiments,
KYM-1 cells were cultured in serum-free S-Clone (Eidia
Co., Ltd, Tokyo, Japan) containing 10 ng/ml basic fibro-
blast growth factor (bFGF).
Flow-cytometric analysis and cell sorting
Cells were conjugated with anti-FGFR3 antibody (R & D,
Minneapolis, MN, USA) for 30 min on ice. Cells were re-
suspended in the same buffer at 1.0 × 107 per ml, and then
kept on ice until analysis. Flow-cytometric analysis was
performed using CyAn™ ADP (Beckman Coulter, Fullerton,
CA, USA). For further analyses, cells were sorted using a
FACSAriaII (BD Biosciences, San Jose, CA) to isolate pure
populations of FGFR3-positive and FGFR3-negative cells.
Generation of adenoviruses
The following viruses were propagated and purified as
described previously [15-19]: E1-deleted replication-
defective adenoviruses; two types of Ads-LacZ that
expressed the LacZ gene under the transcriptional control
of the Rous sarcoma virus long terminal repeat (RSV pro-
moter) (Ad.RSV-LacZ) or the survivin promoter (Ad.
Surv-LacZ); two types of Ads-EGFP that expressed the en-
hanced green fluorescent protein (EGFP) gene under the
cytomegalovirus immediate early gene enhancer/promoter
(CMV promoter) (Ad.CMV-EGFP) or the cytomegalovirus
enhancer and β-actin promoter (CA promoter) (Ad.CA-
EGFP); Ad.dE1.3 that expressed no gene, and Ad.CA-
EGFP/RGD, in which an Arg-Gly-Asp (RGD)-containing
peptide was added to the HI loop of the fiber-knob do-
main of Ad.CA-EGFP. Surv.m-CRA with wild-type E1A
downstream of the survivin promoter, E1B55KD down-
stream of the CMV promoter, and the EGFP gene down-
stream of the CMV promoter was generated as described
previously and used for this study [10-12].
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The adenoviral gene transduction efficiency (AGTE) for
each cell type in vitro was assessed by infecting cells
with Ad.CMV-EGFP at several different multiplicities of
infection (MOIs), detaching the cells 48 h after infection,
and analyzing the percentage of EGFP-positive cells by
flow cytometry [20].
Promoter activities
Promoter activities were examined as described previ-
ously with some modification [15,21]. Briefly, cells (8 ×
105 cells per plate) were infected with Ad.Surv-LacZ or
Ad.RSV-LacZ at an MOI of 30 for 1 h, and then incu-
bated with fresh media. The cells were collected 48 h
post-infection, and β-gal activity was measured using
the β-Galactosidase Enzyme Assay System (Promega,
Madison, WI, USA) as described previously [15,21]. In
addition, expression levels of β-galactosidase in individ-
ual KYM-1 cells were examined by flow cytometry using
the FluoReporter lacZ Flow Cytometry Kit (Molecular
Probes, Leiden, The Netherlands).
Real time quantitative reverse transcription–polymerase
chain reaction (qRT-PCR) analysis
RNA was isolated using Sepasol-RNA I Super G (Nacalai
Tesque, Kyoto, Japan) or the CellAmp Direct RNA Prep
Kit (Takara Bio Inc., Ootsu, Japan), and was subsequently
reverse-transcribed using the PrimeScript II First Strand
cDNA Synthesis Kit (Takara Bio Inc.) [22,23]. RT-PCR
using QuantiFast SYBR Green PCR (Qiagen, Venlo, TheFigure 1 The percentage of FGFR3-positive cells determined by flow-
cells (200× magnification; lower) in each culture condition. KYM-1 cell
serum-minus media containing 10 ng/ml bFGF (B), and subsequently cultu
FGFR3-positive cells and spheres were significantly increased by the serumNetherlands) was performed on a Rotor Gene RG-3000
(Qiagen). The relative mRNA expression levels were de-
termined by the comparative Ct method; expression levels
of individual genes were normalized against the levels of
the reference gene HPRT, which encodes hypoxanthine
guanine phosphoribosyl transferase. The following primer
sets and annealing temperatures were used: survivin,
5- CCAGTGTTTCTTCTGCTTCAA-3 and 5-GAATG
CTTTTTATGTTCCTCTATG-3 at 60°C; HPRT, 5- TGA
CCTTGATTTATTTTGCATACC-3 and 5-CTCGAGCA
AGACGTTCAGTC-3 at 60°C [11,12].
Cytotoxic effects in vitro
Cells in 96-well plates were infected with each adeno-
virus at an MOI of 1, and cell viability was deter-
mined after 3 and 5 days using the WST-8 assay
(Dojindo Laboratories, Mashiki, Japan) as described
previously [11,12,24].
Therapeutic effects in vivo in animal experiments
KYM-1 cells (1 × 106 cells), which had been cultured in
serum-minus media containing S-Clone and 10 ng/ml
bFGF, were mixed with Matrigel (BD Biosciences) and
subcutaneously inoculated into 5-week-old BALB/c nude
mice. After a tumor nodule reached 6–10 mm in diam-
eter, the mice were randomly divided into three groups.
On day 0, a mouse in each group was given a single
intratumoral injection of 150 μL of buffer (10 mmol/L
Tris–HCl pH 7.4, 1 mmol/L MgCl2, 10% glycerol, and
20 μg/mL hexadimethrine bromide) containing 1 × 109cytometric analysis (upper), and microscopic image of KYM-1
s were cultured in serum-plus media (A), then cultured for 3 weeks in
red in the serum-plus media for 1 week (C). The percentages of
-minus culture and decreased by serum-plus culture.
Tanoue et al. Journal of Translational Medicine 2014, 12:27 Page 4 of 13
http://www.translational-medicine.com/content/12/1/27plaque-forming units (pfu) of Surv.m-CRA (n = 6), Ad.
dE1.3 (n = 7), or phosphate-buffered saline (PBS) (n = 8).
Subsequently, tumor size was measured twice a week,
and tumor volume was calculated according to the fol-
lowing formula: volume = long axis × (short axis)2 × 0.5.
For histopathologic analysis, tumors were fixed in 10%
buffered formalin, embedded in paraffin, cut into 4-μm
sections, and stained with hematoxylin and eosin.
All animal studies were performed in accordance with
National Institutes of Health guidelines and with the ap-
proval of the Division of Laboratory Animal Science,
Natural Science Center for Research and Education,
Kagoshima University. All reasonable efforts were made
to minimize suffering.Statistical analysis
Data were represented as the means ± standard errors (s.e.).
Statistical significance was determined using Student’s t



































Figure 2 Adenoviral gene transduction efficiencies (AGTEs) in each cu
or serum-plus conditions were infected for 48 h with Ad.CMV-EGFP at MOI of
(A) and flow-cytometric analysis (B) were performed to assess EGFP-expressin
fluorescence (lower) microscopy are shown at 50× (left) and 200× (right) magResults
RSCs can be maintained, expanded, and differentiated
in vitro
We characterized FGFR3-positive KYM-1 cells as RSCs in
a previous study [7]. Therefore, in this study, we first repro-
duced two distinct culture conditions that successfully in-
duced FGFR3-positive RSC-enriched and FGFR3-negative
RSC-exiguous cell fractions in vitro. Flow-cytometric ana-
lysis revealed that FGFR3-positive cells accounted for only
0.7% of the population when cells were cultured in regular
serum-plus media (Figure 1A). However, the percentage of
FGFR3-positive cells significantly increased, to 7.4% of the
population, after 3-week culture in serum-minus media
(Figure 1B). The population of FGFR3-positive cells was
drastically decreased to 0.8%, i.e., almost to the original
level, only 1 week after the RSC-enriched cell fractions
were returned to culture in regular serum-plus media
(Figure 1C). Sphere formation, which represented clono-
genic growth of the floating cells and was therefore a
useful indication of enrichment of CSCs, was observedFP
54% 72% 78%
I 1 MOI 10 MOI 30
71% 74% 65%
lture condition. Cells that had been cultured under either serum-minus
0 (none), 0.1, 1, 10, or 30. Subsequently, fluorescence-microscopic analysis
g cells. (A) Representative images of phase-contrast (upper) and the
nification. No difference in AGTEs between the two groups was apparent.
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lished two distinct in vitro conditions that allow accur-
ate assessments of survivin and Surv.m-CRAs in RSCs
and their progeny.
AGTEs in KYM-1 cells
KYM-1 cells, cultured in either serum-minus or serum-
plus media, were infected with Ad.CMV-EGFP at vari-
ous MOIs and analyzed by fluorescence microscopy or
flow cytometry to assess AGTEs (Figure 2). AGTEs in
KYM-1 cells were higher than those in other previously
examined cell types [11,12]; however, the difference in
AGTEs between RSC-enriched and RSC-exiguous cells
was not significant, or at least was not drastic. We fur-
ther compared AGTEs between infections with Ad.CA-
EGFP and Ad.CA-EGFP/RGD, because a number of
previous studies demonstrated that modification of the
fiber knob with the RGD peptide increased AGTEs in
some cell types [19]. Fiber modification did not drastic-
ally increase or change AGTEs in KYM-1 cells, either in
RSC-enriched or RSC-exiguous fractions (Figure 3).
Based on these results, we decided to use replication-
defective adenoviral vectors and m-CRAs with wild-type
fibers for subsequent experiments.
Higher expression levels of survivin mRNA in the
FGFR3-positive KYM-1 cell
To assess whether the expression levels of survivin
mRNA were changed in RSCs, we performed qRT-PCR
analyses to make comparisons between RSC-enriched
(serum-minus) and RSC-exiguous (serum-plus) cell frac-
tions and between sorted FGFR3-positive and FGFR3-
negative cells. The RSC-enriched cell fraction exhibited
a slight increase in survivin mRNA level; however, the
difference between the RSC-enriched and RSC-exiguous






















Figure 3 AGTEs of adenoviral vectors with wild or modified fiber. KYM
which have wild-type or modified fiber (RGD-peptide added to the fiber kn
under phase-contrast and fluorescence microscopy 48 h later. Representati
at 50× (left) and 200× (right) magnification. There was no apparent differenWe next examined survivin mRNA levels in sorted
FGFR3-postive and FGFR3-negative cells, because such
an examination in purified FGFR3-positive cells should
make their characteristic phenotypes more apparent. In ac-
cordance with that speculation, survivin mRNA levels in
sorted FGFR3-positive KYM-1 cells were significantly
higher than in FGFR3-negative cells (Figure 4B). These re-
sults suggest that survivin is more highly expressed in
FGFR3-positive RSCs than in FGFR3-negative progeny.
Higher activities of survivin promoter in FGFR3-positive RSCs
We examined the activities of the survivin and control
RSV promoters using replication-defective adenoviral
vectors with the LacZ gene downstream of each of these
promoters. Flow-cytometric analysis revealed that almost
100% of cells expressed LacZ after Ad.RSV-LacZ infec-
tion, and that less than 0.6% of cells were nonspecifically
positive after no infection or infection with Ad.dE1.3
(lacking the transgene); thus, the experimental condi-
tions were appropriate (Figure 4C). The percentages of
cells expressing LacZ under control of the survivin pro-
moter were 8.3 and 5.6% under the RSC-enriched
(serum-minus) and RSC-exiguous (serum-plus) condi-
tions, respectively. Next, we examined the activity of the
survivin promoter relative to that of the RSV promoter,
a representative control promoter with constitutively
strong activity, by measuring β-galactosidase activities
after infection with Ad.Surv-LacZ (Figure 4D and E).
The survivin promoter activity was significantly higher
in RSC-enriched (serum-minus) than in RSC-exiguous
(serum-plus) conditions, and also significantly higher in
sorted FGFR3-positive than in FGFR3-negative cells.
This result, together with the same tendency in en-
dogenous survivin gene expression, suggests that the
survivin promoter, which is highly active in tumor cells
but minimally active in normal cells [11,12], is moreMOI 10 MOI 30
-1 cells were infected with either Ad.CA-EGFP or Ad.CA-EGFP/RGD,
ob), respectively, at an MOI of 0.1, 1, 10, or 30, and then observed
ve phase-contrast (upper) and fluorescence (lower) images are shown
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Figure 4 Survivin mRNA expressions and survivin promoter activity. (A, B) Expression levels of survivin mRNA under serum-minus and
serum-plus conditions (A) and in sorted FGFR3-positive and FGFR3-negative cells (B) were measured by real-time qRT-PCR. The HPRT gene was
amplified as an internal control. (C) Flow-cytometric analysis to detect LacZ-expressing cells 48 h after Ad.Surv-LacZ or Ad.RSV-LacZ infection
at MOI of 30 demonstrated the activities of the survivin and control RSV promoters in individual cells. (D, E) β-galactosidase activities in cells
cultured in serum-minus or serum-plus media (D) and in sorted FGFR3-positive and FGFR3-negative cells (E) were measured after the same
infection described in (C). *, P < 0.05.
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sults confirm that the adenovirally transduced promoter
region functions well in RSCs.
Surv.m-CRA exhibited more efficient replication and
cytotoxicity against RSC-enriched cell fractions in vitro
The construction of the Surv.m-CRA used in this study
is shown in Figure 5A. We first explored apparent viral
replication and the cytotoxic effects of Surv.m-CRAs
against RSC-enriched and RSC-exiguous cell fractionsby microscopically observing the spread of cells express-
ing EGFP and the swollen cells that are a characteristic
feature of the adenoviral cytopathic effect (Figure 5B). In
both fractions, Surv.m-CRA induced prominent viral
replication and cytotoxic effects as early as 3 days after
infection at an MOI of 1. To accurately and quantita-
tively analyze the cytotoxic effect, we performed the
WST viability assay (Figure 5C). Surv.m-CRA potently
induced cell death in both groups. The cytotoxicity was
somewhat more prominent under the RSC-enriched
Figure 5 Viral replication of Surv.m-CRA and cytotoxicity against KYM-1 cells cultured in serum-minus and serum-plus media.
(A) Schematic representation of the construction of Surv.m-CRA. (B) Representative images of phase-contrast and fluorescence-microscopic pictures
5 days after infection with Surv.m-CRA, Ad.dE1.3, or no virus (none) of KYM-1 cells cultured in serum-minus or serum-plus media. Viral replication and
cytopathic effects were prominent in both groups after Surv.m-CRA infection. (C) Cell viability was determined by WST-8 assay 3 or 5 days after
infection.*, P< 0.05. **, P< 0.005. Surv.m-CRA efficiently replicated and potently induced cell death in both cell fractions cultured in serum-minus and
serum-plus media.
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conditions (e.g., P < 0.005 and P < 0.05 between Surv.m-
CRA and Ad.dE1.3 in RSC-enriched and RSC-exiguous,
respectively, on day 5).
Surv.m-CRA exhibited more efficient replication and
cytotoxicity against sorted FGFR3-positive cells in vitro
To directly examine the therapeutic potentials of Surv.
m-CRA against RSCs and progeny, FGFR3-positive
and -negative cells were sorted and subsequently cul-
tured in serum-minus and serum-plus media, respectively.
Whereas FGFR3-positive cells proliferated somewhat more
rapidly than FGFR3-negative cells after sorting and re-
growth, the difference was not drastic (Figure 6A and
Figure 7). Both cell types were infected with Surv.m-
CRA, the control Ad.dE1.3, or no virus (none) 3 days
after the sorting (i.e., when the cells had recovered from
possible damage related to the sorting procedure), and
viral replication and cytotoxic effects were assessed 1, 3,or 5 days later. Efficient viral replication, assessed by the
spread of EGFP-expressing cells, was observed in both
cell types (Figure 6B). In the case of cells infected with
Surv.m-CRA, the number of FGFR3-positive cells was
noticeably smaller than the number of FGFR3-negative
cells after 5 days of growth (Figure 6B and Figure 7).
This result suggests that viral replication and the result-
ing cytotoxic effects of Surv.m-CRA were more promin-
ent in RSCs than in the progeny. According to the
microscopic analysis, the viability assay accurately and
quantitatively demonstrated that the cytotoxicity of
Surv.m-CRA was higher in FGFR3-positive RSCs than
in FGFR3-negative progeny (Figure 6C and Figure 7). A
statistically significant difference in the percentage of
viable cells between Surv.m-CRA–treated and the con-
trol replication-defective Ad.dE1.3–treated groups was
observed in sorted FGFR3-positive cells, but not in
sorted FGFR3-negative cells. Together, the results from










































































FGFR3 + FGFR3 -
Figure 6 Viral replication of Surv.m-CRA and cytotoxicity against sorted FGFR3-positive and FGFR3-negative cells. (A) Growth curves
of sorted cells. Whereas FGFR3-positive cells proliferated somewhat more rapidly than FGFR3-negative cells, the difference was not drastic.
*, P < 0.05. (B) Representative images of phase-contrast and the fluorescence-microscopic pictures 5 days after infection with Surv.m-CRA, Ad.
dE1.3, or no virus. Whereas viral replication and cytopathic effects of Surv.m-CRA were prominent in both groups, the proportion of remaining
cells 5 days after Surv.m-CRA infection at an MOI of 1 was lower in sorted FGFR3-positive cells than in sorted FGFR3-negative cells. (C) Cell viability
was determined by WST-8 assay 3 or 5 days after infection. Cytotoxic effects of Surv.m-CRA were statistically significantly higher than those of Ad.
dE1.3 solely in the sorted FGFR3-positive cells. *, P < 0.05; **, P < 0.005 between Surv.m-CRA and either Ad.dE1.3 or no virus.
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rhabdomyosarcoma cell fractions, including RSCs, and
that such effects were more potent in RSCs than in pro-
geny. This is consistent with the higher survivin expres-
sion levels and promoter activities in RSCs relative to
progeny, shown above (Figure 3).
Surv.m-CRA had potent in vivo therapeutic effects on
tumors generated from RSC-enriched rhabdomyosarcoma
cells in mice
We subcutaneously inoculated RSC-enriched rhabdo-
myosarcoma cells into mice to generate a tumor nodule,
into which Surv.m-CRA (1 × 109 pfu), the control Ad.dE1.3, or no virus (none) was subsequently directly
injected. Periodic measurement of tumor size revealed
that a single intratumoral injection of Surv.m-CRA sig-
nificantly inhibited tumor growth in comparison to Ad.
dE1.3 42 days after adenoviral injection (Figure 8A, B).
By contrast, there was no significant difference in tumor
size on day 42 between the controls, i.e., Ad.dE1.
3–treated and PBS–treated mice. Furthermore, histo-
pathologic analysis of viable and dead tumor cells clearly
demonstrated the potent therapeutic effects of Surv.m-
CRAs beyond what could be shown by the macroscopic
analysis (Figure 8B, C): the macroscopically large tumor
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FGFR3 -
Day 3 Day 5
Figure 7 Viral replication of Surv.m-CRA and cytotoxicity against sorted FGFR3-positive and FGFR3-negative cells. Sorted FGFR3-positive
and FGFR3-negative cells were infected with Surv.m-CRA, Ad.dE1.3, or no virus (none) at an MOI of 1. The cells were observed under phase-
contrast and fluorescence microscopy 1, 3, and 5 days after infection. Representative phase-contrast (upper) and fluorescence (lower) images are
shown at 50× magnification. In the case of no infection (none), FGFR3-positive cells proliferated more rapidly than FGFR3-negative cells after 3
and 5 days. By contrast, the proportion of remaining cells 5 days after Surv.m-CRA infection was lower in FGFR3-positive than in FGFR3-negative
cells. These results suggest that Surv.m-CRA exhibited more efficient replication in and cytotoxicity against sorted FGFR3-positive than
FGFR3-negative cells.
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logical features of active malignancy, including a large
number of mitoses, heterogeneous morphologies of nu-
clei and cells, and densely accumulated cells; in addition,
these tumors contained small and spotty areas consisting
of spontaneous necroses in their centers (Figure 8B, C).
By contrast, the macroscopically small nodules in the
Surv.m-CRA–treated mice consisted histologically of
large necrotic areas with loose connective tissues but no
apparent viable malignant cells. Thus, a single injection
of Surv.m-CRA into tumor nodules generated by im-
plantation of RSC-enriched rhabdomyosarcoma cells in
mice exhibited a potent therapeutic effect in vivo.
Discussion
We previously showed that Surv.m-CRAs could treat a
broad range of cancer types more efficiently and safely (i.e.,
cancer-specifically) than Tert.m-CRAs, which are among
the best CRAs [11,12,25]. The results of this study demon-
strate not only that Surv.m-CRAs can efficiently kill all
populations of rhabdomyosarcoma cells, including both
RSCs and their progeny (i.e., the bulk of malignant cells),
but also that the antitumor effects of Surv.m-CRAs are
higher against RSCs. This feature is clinically meaningful
and promising because the therapeutic mode of Surv.m-
CRAs is opposite to that of conventional chemoradiothera-
pies, and because Surv.m-CRA may overcome, at least in
part, the serious drawbacks of current cancer treatments.
Some previous studies assessed the cytotoxic effects
of oncolytic viruses on CSCs [26], and several groupsreported that their CRAs might be effective against
stem-like cancer cells of glioblastoma [27,28], esophageal
cancer [29], and breast cancer [30]. However, the efficacy
of these CRAs against CSCs was not accurately estab-
lished in these studies, due to limitations of the analyses
or the CSC models used. From the standpoint of the
analyses, the lack of point-by-point comparisons of bio-
logical features, both regarding genes that regulated viral
replication and the differences in the effects of CRAs be-
tween sorted CSCs and progeny, led to unclear conclu-
sions regarding the most important question: how
efficiently do these viruses kill CSCs in comparison to
their progeny [27,28]? From the standpoint of the CSC
models, some previous studies used radioresistant cancer
cells as cancer stem-like cells, but did not examine
sorted CSCs [28]. Although radiation treatment may en-
rich CSCs, the radioresistant cancer cells are not equiva-
lent to CSCs. Thus, although the previous studies did
provide some important information, their results may not
allow a generalized assessment regarding the potentials of
CRAs against CSCs. Therefore, the efficacy of each
oncolytic virus and CRA against CSCs should be indi-
vidually and carefully assessed in the proper experimen-
tal models.
To accurately assess the biological features and thera-
peutic potential of Surv.m-CRAs against CSCs, in a previ-
ous study we identified FGFR3 as a useful marker that
allows accurate monitoring and purification of RSCs; a
single implanted FGFR3-positive rhabdomyosarcoma cell




























Days after intratumor injection
Figure 8 In vivo therapeutic effects of Surv.m-CRA against tumors in mice. Tumor nodules were generated in mice by implantation of
RSC-enriched rhabdomyosarcoma cells, and a single intratumoral injection of Surv.m-CRA, Ad.dE1.3, or PBS was subsequently administered to
each nodule. (A) The macroscopic tumor size after each treatment. A significant difference was found between mice treated with Surv.m-CRA
and those treated with either control (Ad.dE1.3 or PBS) (P < 0.05). (B) Representative macroscopic pictures of a tumor nodule 42 days after each
treatment. (C) Representative histopathologic pictures of hematoxylin/eosin-stained sections in the tumor nodule 42 days after each treatment. In
Ad.dE1.3-treated and the PBS-treated mice, tumor nodules mainly consisted of viable tumor cells exhibiting malignant features without large
necrotic areas. By contrast, in Surv.m-CRA–treated mice, tumor nodules mainly consisted of large necrotic areas with loose connective tissues
and without viable tumor cells. Original magnification: 40× (top; scale bar, 1 mm) and 400× (bottom; scale bar, 100 mm).
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http://www.translational-medicine.com/content/12/1/27cells did not form tumors [7]. Because FGFR3-positive
rhabdomyosarcoma cells, including KYM-1 cells, were
characterized as RSCs in our previous study, it was not ne-
cessary to repeat this characterization in this study. Based
on those results, in this study we carefully compared the
biological features of survivin (both endogenous gene ex-
pression and the transduced promoter activity) and Surv.
m-CRAs, both between RSC-enriched and RSC-exiguousconditions and between purified FGFR3-positive RSCs
and purified FGFR3-negative progeny cells. We used both
of these experimental systems because the former
(enriched CSCs together with some progeny cells) may, at
least in part, reflect the in vivo microenvironment,
whereas the latter (purified CSCs) may facilitate clarifica-
tion of the biological differences between CSCs and pro-
genitor cells. Analyses in both experimental systems
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which has already been shown to have stronger and more
cancer-specific activity than the Tert promoter [11,12],
was further increased in RSCs; indeed, Surv.m-CRAs effi-
ciently killed all populations with the desirable property of
increased therapeutic efficacy against RSCs.
On the other hand, the movements and changes of
CSCs within the body are not fully understood, and
these points can be accurately addressed in only a few
animal models. In addition, human type 5 adenovirus,
which is the backbone of Surv.m-CRAs, can infect
mouse cells but cannot replicate in mice; therefore, there
is no available animal model in which the therapeutic ef-
ficacy of CRAs against CSCs can be accurately analyzed.
Therefore, we assessed the therapeutic efficiency of
Surv.m-CRAs in tumor nodules generated by implant-
ation of RSC-enriched rhabdomyosarcoma cells; Surv.m-
CRAs exhibited a potent in vivo therapeutic effect in this
animal model. Although the in vivo efficacy of Surv.m-
CRAs against CSCs cannot be quantitatively assessed,
this result demonstrates the therapeutic efficacy and the
possible clinical utility of Surv.m-CRAs for treating
rhabdomyosarcoma.
The RGD-based fiber modification allows the adeno-
virus to use integrins as alternative receptors during the
cell entry process, and increases AGTEs in certain cell
types, particularly those that lack the expression of the na-
tive Coxsackie-adenovirus receptor [31]. In contrast to a
previous report that fiber-modified CRA increased thera-
peutic efficacy against CSCs of glioma [27], in our hands
the fiber modification did not drastically increase AGTEs.
Therefore, we did not need to modify the fibers of Surv.




















Figure 9 The putative therapeutic advantage of m-CRA virotherapy. I
decreased in the advanced malignant tumor cells, and in particular, CSCs a
m-CRA virotherapy can efficiently kill all populations of malignant tumor ce
m-CRA virotherapy are higher against CSCs.this model. The clinical utility of the fiber modification
may depend on the adenoviral infectivity in each cell type.
Together with the previous findings, the results of this
study suggest the possible therapeutic efficacy of Surv.m-
CRAs against other types of CSCs. Clinical studies previ-
ously demonstrated that high survivin expression levels are
positively correlated with poor prognosis, accelerated rate of
recurrence, and increased resistance to therapy in a variety
of cancer types, including rhabdomyosarcoma [5,13,14]. Our
results reported here regarding up-regulated survivin ex-
pression and survivin promoter activity in RSCs are consist-
ent with the clinical findings, and should therefore be
considered reasonable. Because a close relationship between
higher expression levels of survivin and more malignant
phenotypes has been observed in a variety of cancer types,
the potent efficacy of Surv.m-CRAs to the RSCs revealed in
this study may be applicable to other types of CSCs.
In terms of mechanism, accumulated data have re-
vealed that survivin is involved in apoptosis resistance
and proliferation of cancer cells, mediated at least in
part through the responses to various growth factors, in-
cluding bFGF [32,33]. bFGF up-regulates survivin ex-
pression in certain cancer cells [32], and survivin plays
an essential role in angiogenesis in tumors by up-
regulating bFGF expression [33], leading to activation of
the FGFR3-mediated signaling pathway [7]. Any mech-
anistic inference based on these findings would necessar-
ily be speculative, however, and the overall molecular
mechanism underlying the relationship between the sur-
vivin expression and malignant features of CSCs should
be clarified by extensive future studies.
This study provides general and important information
that should be useful in the development of oncolyticm-CRA virotherapy
Not only the effectiveness
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very few successful reports of transcriptional targeting of
oncolytic viruses against CSCs. In particular, none of the
previous reports clearly showed that oncolytic viruses
successfully acquired increased therapeutic efficacy
against CSCs in parallel to increases in promoter activity
and expression of a target gene. In this study, expression
and promoter activity of survivin were further increased
in CSCs; as a result of these transcriptional changes,
Surv.m-CRAs exerted increased therapeutic efficacy
against CSCs. Although the replicative mechanisms of
adenoviruses have not been fully elucidated, the results
described here suggest that the promising features of
Surv.m-CRA may be due partly to specific features of
adenoviruses and partly to the function of the survivin
gene. Taken together, these findings demonstrate that
Surv.m-CRA is an effective anticancer agent, but more
generally, the results indicate that the use of m-CRAs rep-
resents a promising strategy for the development of effect-
ive anticancer agents against CSCs (Figure 9). In other
words, the results described here pave the way to future
development of several effective m-CRA–based therapies
against CSCs; future progress will proceed via identifica-
tion of new genes that target CSCs and generation of new
m-CRAs using the promoters of these genes.
Conclusion
Surv.m-CRAs demonstrated not only therapeutic effi-
cacy against all the populations of rhabdomyosarcoma,
but also increased efficacy against RSCs. These results
will facilitate the clinical application of Surv.m-CRAs,
and should be useful for future development of oncolytic
virotherapies that target CSCs.
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